On June 11 biotech companies Moderna announced that the plans for the Phase 3 trial had completed his COVID-19 vaccine candidates. The study will include 30,000 participants at an advanced stage and is expected to begin in July. The study is only a test of the vaccine dose, 100 micrograms, given in two shots. In the Phase 1 study with 45 healthy volunteers previously it examined the company lower and higher doses, but showed preliminary results that suggested by the company from this study is that 100 micrograms guaranteed the desired immune response. According to the company, the vaccine produced antibodies against the virus COVID-19 in those who were vaccinated, and involved a handful of test participants, these antibodies were able to neutralize the virus in the laboratory. Full details of this study are not yet available; which will be published shortly by the staff Modern, a team of scientists from the National Institute of Allergy and Infectious Diseases. The Phase 2 study is ongoing and will enroll 600 healthy people who follow a year after the injections. This phase will continue trying to collect more data for their effectiveness in the safety of the vaccine. This study will include more people who may be at high risk of exposure to COVID-19, such as health care workers and residents in long term care facilities. In June, it was Modern Operating President Trump Warp Speed program to be the chosen one of five vaccine developers of the development of the speed of a COVID-19 vaccine. The selection of qualified Modern federal government loans received vaccine development, lead to continue testing, and scale-up of production of the target will begin to vaccinate 300 million people start to meet early next year. Modern said it expects 500 million to 1 billion doses in 2021 begin to provide one year.